Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 2, Dose-finding Study to Investigate the Efficacy and Safety of SAR445399 in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07225569 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled, Phase 2, Dose-finding Study to Investigate the Efficacy and Safety of SAR445399 in Participants With Moderate to Severe Hidradenitis Suppurativa
- Lead sponsor
- Sanofi
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- December 29, 2025
- Completion date
- November 19, 2027
- Enrollment
- 144 (estimated)
- Sites
- 83
Conditions
As the registry lists them; a condition with its own page is linked.